RecruitingNCT06135909

CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy

Sponsor

Chinese Pulmonary Vascular Disease Research Group

Enrollment

5,000 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)

Min Age: 18 YearsMax Age: 85 Years

Sign informed consent;
Between the ages of 18 and 85;
Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).

Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
Patients with malignant tumor and other diseases and life expectancy of less than half a year;
Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension